洛哌丁胺致心脏心律失常成功应用VA-ECMO、MARS与CRRT支持治疗
本文报道一例36岁女性因每日服用洛哌丁胺400-600 mg出现宽QRS心动过缓、低血压、多形性室性心动过速,对多种ACLS方案无效,启动VA-ECMO后血流动力学立即稳定。最高洛哌丁胺及N-去甲基洛哌丁胺水平分别为32和500 ng/ml。因药物与蛋白结合,启用MARS清除毒素,并因急性肾衰竭使用CRRT,最终于住院第12天脱离ECMO、MARS和CRRT,神经功能完好出院。作者认为,对于致死性洛哌丁胺心脏毒性,应考虑VA-ECMO(或转诊至具备VA-ECMO的中心)。
要点
- 洛哌丁胺滥用(每日400-600 mg)可导致宽QRS心动过缓、低血压及难治性多形性室性心动过速,对多种ACLS方案无效。
- 对致死性洛哌丁胺心脏毒性,VA-ECMO可立即稳定血流动力学,为药物自然清除提供时间。
- 洛哌丁胺及代谢物蛋白结合率高,本病例使用MARS试图清除毒素,但连续水平监测未能证明药物清除。
- 患者合并急性肾衰竭,接受CRRT支持,最终于住院第12天脱离ECMO、MARS和CRRT,神经功能完好出院。
- 作者认为,VA-ECMO(或转诊至具备VA-ECMO的中心)应考虑用于致死性洛哌丁胺诱导的心脏毒性,或许也适用于其他心脏毒素。
适用人群与场景
- 洛哌丁胺大量滥用(每日400-600 mg)导致致死性心脏毒性的患者。
处置流程与药物剂量
- 对多种ACLS方案无效的难治性多形性室性心动过速,启动VA-ECMO后血流动力学立即稳定。
- 因洛哌丁胺及代谢物蛋白结合,启用MARS清除毒素。
- 急性肾衰竭时使用CRRT支持。
- 最终脱离ECMO、MARS和CRRT,住院第12天神经功能完好出院。
红旗征与不能漏的情况
- 宽QRS心动过缓、血压测不出、低体温、呼吸浅慢和低血糖,提示洛哌丁胺严重中毒。
- 心律蜕变为多形性室性心动过速且对多种ACLS方案无效,需考虑VA-ECMO支持。
研究设计与关键结果
- 病例报告:36岁女性,每日服用洛哌丁胺400-600 mg,出现宽QRS心动过缓、血压测不出、低体温、呼吸浅慢和低血糖,心律蜕变为多形性室性心动过速,对多种ACLS方案无效。
- 启动VA-ECMO后立即稳定;最高洛哌丁胺和N-去甲基洛哌丁胺水平分别为32和500 ng/ml。
- 启用MARS清除毒素,但连续水平监测未能证明药物清除;因急性肾衰竭使用CRRT。
- 最终脱离ECMO、MARS和CRRT,住院第12天神经功能完好出院。
证据类型、等级与局限
- 病例报告。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于致死性洛哌丁胺诱导的心脏毒性,应考虑VA-ECMO(或转诊至具备VA-ECMO的中心),或许也适用于其他心脏毒素。
- VA-ECMO可提供血流动力学支持,为洛哌丁胺心脏毒性的自然缓解争取时间。
- MARS用于高蛋白结合毒素时,药物清除效果未能通过连续水平监测证实。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: This case of Loperamide misuse had refractory ventricular arrhythmias and was successfully supported by VA ECMO. Loperamide is currently available without prescription and can be obtained in large quantities over the internet despite Food and Drug Administration (FDA) 2016 black box warning noting cardiac toxicity. This case illustrates the life-threatening toxicity of loperamide and suggests a supportive modality to provide clinical time while the drug is cleared endogenously or exogenously. Case report: A 36-year-old female was found minimally responsive. Vital signs and monitoring revealed wide complex bradycardia, undetectable blood pressure, hypothermia, bradypnea, and hypoglycemia. The rhythm degenerated to polymorphic ventricular tachycardia cardia refractory to multiple ACLS protocols. VA-ECMO was initiated with immediate stabilization. Subsequent history revealed massive consumption of loperamide taking 400-600 mg daily. Highest known loperamide and N-desmethyl-loperamide levels were 32 and 500 ng/ml respectively. Since loperamide and metabolites are known to be protein bound, molecular adsorbent recirculating system (MARS) was initiated for toxin clearance. Additionally, she developed acute renal failure supported by CRRT. She was ultimately weaned from ECMO, MARS, and CRRT and discharged neurologically intact on hospital day 12. Discussion: VA ECMO for hemodynamic support provided the needed time for natural resolution of the cardiac toxicity while providing adequate perfusion. MARS was used in the setting of highly protein bound toxins, but drug clearance could not be demonstrated through serial levels. VA ECMO (or referral to a center with VA ECMO) should be considered with lethal loperamide-induced cardiotoxicity and perhaps other cardio-toxins.
参考来源
- Parker BM, Rao T, Matta A, et al. Loperamide induced cardiac arrhythmia successfully supported with veno-arterial ECMO (VA-ECMO), molecular adsorbent recirculating system (MARS) and continuous renal replacement therapy (CRRT). Clin Toxicol (Phila). 2019. PMID: 30806091. doi:10.1080/15563650.2019.1580370
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。